Holen Sie sich die Stockscreener-App
11.59
1.70%
-0.20
Handel nachbörslich:
11.64
0.05
+0.43%
Schlusskurs vom Vortag:
$11.79
Offen:
$11.76
24-Stunden-Volumen:
1.98M
Relative Volume:
1.01
Marktkapitalisierung:
$989.56M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-12.60
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
-22.58%
1M Leistung:
-8.74%
6M Leistung:
+41.00%
1J Leistung:
+181.31%
1-Tages-Spanne:
$11.45
$11.86
1-Wochen-Bereich:
$11.45
$15.13
52-Wochen-Spanne:
$3.61
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
11.59 | 989.56M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Despite shrinking by US$64m in the past week, CorMedix (NASDAQ:CRMD) shareholders are still up 366% over 3 years - simplywall.st
CorMedix stock rises after earnings, revenue beat - MSN
CorMedix stock soars to 52-week high, hits $15.33 By Investing.com - Investing.com South Africa
CorMedix stock soars to 52-week high, hits $15.33 - Investing.com Australia
Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com
Cormedix anticipates Q2 revenue at high end of $23M-$31M range with inpatient growth accelerating - MSN
CorMedix at Jefferies Healthcare: Strategic Expansion and Financial Growth By Investing.com - Investing.com Canada
CorMedix at Jefferies Healthcare: Strategic Expansion and Financial Growth - Investing.com Australia
CorMedix stock rises as Q1 earnings and revenue surpass estimates By Investing.com - Investing.com Nigeria
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position - Seeking Alpha
CorMedix:Exceeding Expectations (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc. to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference - The Manila Times
CorMedix Brings Latest Therapeutic Developments to Jefferies Healthcare Conference 2025 - Stock Titan
(CRMD) Trading Advice - news.stocktradersdaily.com
CorMedix Inc. (CRMD) Stock Analysis: Unveiling a 37.30% Potential Upside in Healthcare Biotechnology - DirectorsTalk Interviews
CorMedix at RBC Capital Markets: Strategic Expansion and Growth - Investing.com Australia
CorMedix at RBC Capital Markets: Strategic Expansion and Growth By Investing.com - Investing.com India
CorMedix Inc. to Participate in the RBC Global Healthcare Conference - The Manila Times
CorMedix Inc. to Participate in RBC Capital Markets Global Healthcare Conference on May 21, 2025 - Nasdaq
Leading Biopharma CorMedix Set for Key Presentation at RBC Healthcare Conference Next Week - Stock Titan
CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement - ACCESS Newswire
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock - Yahoo Finance
Market Highlights: CorMedix Inc (CRMD) Ends on a High Note at 12.03 - DWinneX
CorMedix Inc. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
CorMedix Inc. (CRMD): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential - Insider Monkey
Cormedix (CRMD) Receives a Buy from RBC Capital - The Globe and Mail
CorMedix at Citizens JMP: Strategic Growth and Market Expansion By Investing.com - Investing.com Nigeria
CorMedix at Citizens JMP: Strategic Growth and Market Expansion - Investing.com
CorMedix Inc. (NASDAQ:CRMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Just Shipped A Substantial Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Estimates - Yahoo Finance
CorMedix Inc. Reports Strong Q1 Earnings and Positive Outlook - MSN
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates - MSN
(CRMD) Investment Analysis - news.stocktradersdaily.com
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises - Investing.com Nigeria
Cormedix Inc (CRMD) Q1 2025 Earnings Call Highlights: Record Profitability and Strategic Growth ... By GuruFocus - Investing.com Canada
CorMedix Inc. Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises By Investing.com - Investing.com South Africa
CorMedix: Q1 Earnings Snapshot - Norwalk Hour
CorMedix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRMD Price Target Increased as Positive Momentum Builds | CRMD S - GuruFocus
CorMedix Shares Soar After Q1 Earnings, Revenue Beat Consensus - MarketScreener
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025 - The Globe and Mail
Cormedix Inc (CRMD) Q1 2025 Earnings: EPS of $0.32 Beats Estimat - GuruFocus
CorMedix (CRMD) Surpasses Revenue and EPS Expectations in Q1 - GuruFocus
CRMD Price Target Increased as Positive Momentum Builds | CRMD Stock News - GuruFocus
CorMedix Inc. Revises Sales Guidance for the First Half of 2025 - marketscreener.com
CorMedix (CRMD) Surges on Strong Q1 Earnings - GuruFocus
CorMedix Inc (NASDAQ: CRMD): Hidden Gems In A Time Of Volatility - Stocksregister
CRMD Stock Rating and Price Target Maintained by Analyst | CRMD - GuruFocus
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
CorMedix Inc-Aktie (CRMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Todisco Joseph | Chief Executive Officer |
Apr 01 '25 |
Option Exercise |
3.38 |
59,170 |
199,995 |
530,721 |
| Mistry Erin | EVP, Chief Commercial Officer |
Oct 31 '24 |
Buy |
9.99 |
1,500 |
14,985 |
52,011 |
| Hurlburt Elizabeth | EVP |
Nov 14 '24 |
Option Exercise |
4.48 |
140,027 |
627,727 |
185,424 |
| Hurlburt Elizabeth | EVP |
Nov 14 '24 |
Sale |
11.18 |
140,027 |
1,565,670 |
45,397 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):